Major trials tracked
Cardiometabolic & renal · Live ClinicalTrials.gov data
Finerenone (Kerendia) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 finerenone (Kerendia) trials on ClinicalTrials.gov by enrolment, 5 of them actively recruiting. The next phase 3 primary completion among them is expected Nov 2027. Refreshed daily. Add up to four competitors to compare pipelines side by side.
Phase 3 trials
Actively recruiting
Next phase 3 primary completion
Participants across trials
Lead sponsor by trial count
finerenone
Upcoming readouts
7 ahead · finerenone
Key finerenone trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track finerenone with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Related drug pipelines
FAQ
- How many clinical trials are running for finerenone?
- ClinicalTrials.gov lists more than 16 phase 2–4 finerenone trials. This page tracks the 16 largest by enrolment: 2 phase 2, 8 phase 3, and 6 phase 4 among them, with 5 actively recruiting. Updated daily.
- Are there clinical trials for Kerendia?
- Kerendia is the brand name for finerenone, so finerenone trials on ClinicalTrials.gov cover it. ClinicalTrials.gov lists more than 16 phase 2–4 finerenone trials. This page tracks the 16 largest by enrolment: 2 phase 2, 8 phase 3, and 6 phase 4 among them, with 5 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare finerenone against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.